A cell-penetrating phospholamban-specific RNA aptamer enhances Ca2+ transients and contractile function in cardiomyocytes

Journal of Molecular and Cellular Cardiology

Volumn 76, Issue , 2014, Pages 177-185

  Sakai, Hiroki ^a   Ikeda, Yasuhiro ^a   Honda, Takeshi ^a   Tanaka, Yoshie ^a   Shiraishi, Kozo ^a   Inui, Makoto ^a  

^a YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Aptamer; Calcium signaling; Cardiac sarcoplasmic reticulum; Cardiomyocyte; Cell penetrating peptide; Phospholamban

Indexed keywords

ADENOSINE TRIPHOSPHATASE; ALPHA ADRENERGIC RECEPTOR; APTAMER; CALCIUM ION; CARDIOVASCULAR AGENT; CELL PENETRATING PEPTIDE; HYBRID PROTEIN; MTAT PEPTIDE RNA APTAMER 30 CONJUGATE; MTAT PEPTIDE RNA SARCOMERE 30 CONJUGATE; PHOSPHOLAMBAN; PHOSPHOROTHIOIC ACID; PROPRANOLOL; UNCLASSIFIED DRUG; CALCIUM BINDING PROTEIN; PROTEIN BINDING; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CALCIUM SIGNALING; CALCIUM TRANSPORT; COMBINATORIAL CHEMISTRY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BINDING; DRUG CONJUGATION; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; HEART CONTRACTION; HEART FAILURE; HEART FUNCTION; HEART MUSCLE CELL; HUMAN; IN VITRO SELECTION; MALE; MUSCULOSKELETAL SYSTEM PARAMETERS; NONHUMAN; PROTEIN TARGETING; RAT; SARCOMERE SHORTENING; ANIMAL; CELL CULTURE; CHEMISTRY; DOG; DRUG EFFECTS; METABOLISM; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PHYSIOLOGY; RABBIT; SARCOPLASMIC RETICULUM; WISTAR RAT;

ANIMALS; APTAMERS, NUCLEOTIDE; BASE SEQUENCE; CALCIUM SIGNALING; CALCIUM-BINDING PROTEINS; CELL-PENETRATING PEPTIDES; CELLS, CULTURED; DOGS; MALE; MOLECULAR SEQUENCE DATA; MYOCARDIAL CONTRACTION; MYOCYTES, CARDIAC; PROTEIN BINDING; RABBITS; RATS, WISTAR; SARCOPLASMIC RETICULUM; SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES;

EID: 84907760103     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2014.09.006     Document Type: Article

References (44)

1. Fleischer S., Inui M. Biochemistry and biophysics of excitation-contraction coupling. Annu Rev Biophys Biophys Chem 1989, 18:333-364.
2. MacLennan D.H., Kranias E.G. Phospholamban: a crucial regulator of cardiac contractility. Nat Rev Mol Cell Biol 2003, 4:566-577.
3. Tada M., Katz A.M. Phosphorylation of the sarcoplasmic reticulum and sarcolemma. Annu Rev Physiol 1982, 44:401-423.
4. 2+ transport as studied by reconstitution of cardiac sarcoplasmic reticulum. J Biol Chem 1986, 261:1794-1800.
5. 2+ pump of sarcoplasmic reticulum. Nature 1989, 342:90-92.
6. 2+ uptake in mammalian ventricular myocytes. Am J Physiol 1991, 261:H1344-H1349.
7. Luo W., Grupp I.L., Harrer J., Ponniah S., Grupp G., Duffy J.J., et al. Targeted ablation of the phospholamban gene is associated with markedly enhanced myocardial contractility and loss of beta-agonist stimulation. Circ Res 1994, 75:401-409.
8. Tada M., Inui M. Regulation of calcium transport by the ATPase-phospholamban system. J Mol Cell Cardiol 1983, 15:565-575.
9. Kranias E.G., Hajjar R.J. Modulation of cardiac contractility by the phospholamban/SERCA2a regulatome. Circ Res 2012, 110:1646-1660.
10. Minamisawa S., Hoshijima M., Chu G., Ward C.A., Frank K., Gu Y., et al. Chronic phospholamban-sarcoplasmic reticulum calcium ATPase interaction is the critical calcium cycling defect in dilated cardiomyopathy. Cell 1999, 99:313-322.
11. Hoshijima M., Ikeda Y., Iwanaga Y., Minamisawa S., Date M.O., Gu Y., et al. Chronic suppression of heart-failure progression by a pseudophosphorylated mutant of phospholamban via in vivo cardiac rAAV gene delivery. Nat Med 2002, 8:864-871.
12. Iwanaga Y., Hoshijima M., Gu Y., Iwatate M., Dieterle T., Ikeda Y., et al. Chronic phospholamban inhibition prevents progressive cardiac dysfunction and pathological remodeling after infarction in rats. J Clin Invest 2004, 113:727-736.
13. Kaye D.M., Preovolos A., Marshall T., Byrne M., Hoshijima M., Hajjar R., et al. Percutaneous cardiac recirculation-mediated gene transfer of an inhibitory phospholamban peptide reverses advanced heart failure in large animals. J Am Coll Cardiol 2007, 50:253-260.
14. Dieterle T., Meyer M., Gu Y., Belke D.D., Swanson E., Iwatate M., et al. Gene transfer of a phospholamban-targeted antibody improves calcium handling and cardiac function in heart failure. Cardiovasc Res 2005, 67:678-688.
15. 2+-ATPase activity and left ventricular function in STZ-induced diabetic rats. Biomed Environ Sci 2013, 26:577-583.
16. Suckau L., Fechner H., Chemaly E., Krohn S., Hadri L., Kockskamper J., et al. Long-term cardiac-targeted RNA interference for the treatment of heart failure restores cardiac function and reduces pathological hypertrophy. Circulation 2009, 119:1241-1252.
17. Bish L.T., Sleeper M.M., Reynolds C., Gazzara J., Withnall E., Singletary G.E., et al. Cardiac gene transfer of short hairpin RNA directed against phospholamban effectively knocks down gene expression but causes cellular toxicity in canines. Hum Gene Ther 2011, 22:969-977.
18. Lee J.F., Stovall G.M., Ellington A.D. Aptamer therapeutics advance. Curr Opin Chem Biol 2006, 10:282-289.
19. Ni X., Castanares M., Mukherjee A., Lupold S.E. Nucleic acid aptamers: clinical applications and promising new horizons. Curr Med Chem 2011, 18:4206-4214.
20. Ellington A.D., Szostak J.W. In vitro selection of RNA molecules that bind specific ligands. Nature 1990, 346:818-822.
21. Tuerk C., Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 1990, 249:505-510.
22. Tanaka Y., Honda T., Matsuura K., Kimura Y., Inui M. In vitro selection and characterization of DNA aptamers specific for phospholamban. J Pharmacol Exp Ther 2009, 329:57-63.
23. Xu A., Chen K.Y. Hypusine is required for a sequence-specific interaction of eukaryotic initiation factor 5A with postsystematic evolution of ligands by exponential enrichment RNA. J Biol Chem 2001, 276:2555-2561.
24. 2+ pump ATPase. J Biol Chem 1992, 267:1674-1679.
25. Tada M., Inui M., Yamada M., Kadoma M., Kuzuya T., Abe H., et al. Effects of phospholamban phosphorylation catalyzed by adenosine 3':5'-monophosphate- and calmodulin-dependent protein kinases on calcium transport ATPase of cardiac sarcoplasmic reticulum. J Mol Cell Cardiol 1983, 15:335-346.
26. Ho A., Schwarze S.R., Mermelstein S.J., Waksman G., Dowdy S.F. Synthetic protein transduction domains: enhanced transduction potential in vitro and in vivo. Cancer Res 2001, 61:474-477.
27. Kajstura J., Cigola E., Malhotra A., Li P., Cheng W., Meggs L.G., et al. Angiotensin II induces apoptosis of adult ventricular myocytes in vitro. J Mol Cell Cardiol 1997, 29:859-870.
28. Milligan J.F., Uhlenbeck O.C. Determination of RNA-protein contacts using thiophosphate substitutions. Biochemistry 1989, 28:2849-2855.
29. Kang J., Lee M.S., Watowich S.J., Gorenstein D.G. Combinatorial selection of a RNA thioaptamer that binds to Venezuelan equine encephalitis virus capsid protein. FEBS Lett 2007, 581:2497-2502.
30. Eckstein F. Phosphorothioate oligodeoxynucleotides: what is their origin and what is unique about them?. Antisense Nucleic Acid Drug Dev 2000, 10:117-121.
31. Metcalfe E.E., Traaseth N.J., Veglia G. Serine 16 phosphorylation induces an order-to-disorder transition in monomeric phospholamban. Biochemistry 2005, 44:4386-4396.
32. Thiel K.W., Giangrande P.H. Intracellular delivery of RNA-based therapeutics using aptamers. Ther Deliv 2010, 1:849-861.
33. Letsinger R.L., Zhang G.R., Sun D.K., Ikeuchi T., Sarin P.S. Cholesteryl-conjugated oligonucleotides: synthesis, properties, and activity as inhibitors of replication of human immunodeficiency virus in cell culture. Proc Natl Acad Sci U S A 1989, 86:6553-6556.
34. Heitz F., Morris M.C., Divita G. Twenty years of cell-penetrating peptides: from molecular mechanisms to therapeutics. Br J Pharmacol 2009, 157:195-206.
35. 2+-ATPase in patients with advanced heart failure. Circulation 2011, 124:304-313.
36. Zhang H.S., Liu D., Huang Y., Schmidt S., Hickey R., Guschin D., et al. A designed zinc-finger transcriptional repressor of phospholamban improves function of the failing heart. Mol Ther 2012, 20:1508-1515.
37. Miyazaki Y., Ikeda Y., Shiraishi K., Fujimoto S.N., Aoyama H., Yoshimura K., et al. Heart failure-inducible gene therapy targeting protein phosphatase 1 prevents progressive left ventricular remodeling. PLoS One 2012, 7:e35875.
38. Eckhouse S.R., Jones J.A., Spinale F.G. Gene targeting in ischemic heart disease and failure: translational and clinical studies. Biochem Pharmacol 2013, 85:1-11.
39. Haghighi K., Kolokathis F., Pater L., Lynch R.A., Asahi M., Gramolini A.O., et al. Human phospholamban null results in lethal dilated cardiomyopathy revealing a critical difference between mouse and human. J Clin Invest 2003, 111:869-876.
40. Song Q., Schmidt A.G., Hahn H.S., Carr A.N., Frank B., Pater L., et al. Rescue of cardiomyocyte dysfunction by phospholamban ablation does not prevent ventricular failure in genetic hypertrophy. J Clin Invest 2003, 111:859-867.
41. C transgenic mice. Circ Res 2010, 106:354-362.
42. 2+ overload. J Mol Cell Cardiol 2012, 53:233-239.
43. Di Carlo M.N., Said M., Ling H., Valverde C.A., De Giusti V.C., Sommese L., et al. CaMKII-dependent phosphorylation of cardiac ryanodine receptors regulates cell death in cardiac ischemia/reperfusion injury. J Mol Cell Cardiol 2014, 74:274-283.
44. Asp M.L., Martindale J.J., Heinis F.I., Wang W., Metzger J.M. Calcium mishandling in diastolic dysfunction: mechanisms and potential therapies. Biochim Biophys Acta 1833, 2013:895-900.